Monopar Therapeutics 관리

관리 기준 확인 2/4

Monopar Therapeutics CEO는 Chandler Robinson, Dec2014 에 임명되었습니다 의 임기는 9.92 년입니다. 총 연간 보상은 $ 1.78M, 32.6% 로 구성됩니다. 32.6% 급여 및 67.4% 보너스(회사 주식 및 옵션 포함). 는 $ 1.13M 가치에 해당하는 회사 주식의 1.06% 직접 소유합니다. 1.13M. 경영진과 이사회의 평균 재임 기간은 각각 5.7 년과 8.8 년입니다.

주요 정보

Chandler Robinson

최고 경영자

US$1.8m

총 보상

CEO 급여 비율	32.6%
CEO 임기	9.9yrs
CEO 소유권	1.1%
경영진 평균 재임 기간	5.7yrs
이사회 평균 재임 기간	8.8yrs

최근 관리 업데이트

Recent updates

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Aug 13

Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Feb 27

Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?

Mar 02

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Nov 16

Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of Validive

Oct 05

We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate

Jul 30

Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

Mar 28

We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely

Jul 15

Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Mar 26

CEO 보상 분석

Chandler Robinson 의 보수는 Monopar Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$6m
Jun 30 2024	n/a	n/a	-US$7m
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	US$2m	US$580k	-US$8m
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$2m	US$550k	-US$11m
Sep 30 2022	n/a	n/a	-US$10m
Jun 30 2022	n/a	n/a	-US$10m
Mar 31 2022	n/a	n/a	-US$10m
Dec 31 2021	US$1m	US$525k	-US$9m
Sep 30 2021	n/a	n/a	-US$9m
Jun 30 2021	n/a	n/a	-US$8m
Mar 31 2021	n/a	n/a	-US$7m
Dec 31 2020	US$2m	US$504k	-US$6m
Sep 30 2020	n/a	n/a	-US$5m
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	-US$4m
Dec 31 2019	US$541k	US$386k	-US$4m
Sep 30 2019	n/a	n/a	-US$4m
Jun 30 2019	n/a	n/a	-US$4m
Mar 31 2019	n/a	n/a	-US$4m
Dec 31 2018	US$1m	US$375k	-US$3m
Sep 30 2018	n/a	n/a	-US$3m
Jun 30 2018	n/a	n/a	-US$17m
Mar 31 2018	n/a	n/a	-US$17m
Dec 31 2017	US$401k	US$331k	-US$17m

보상 대 시장: Chandler 의 총 보상 ($USD 1.78M )은 US 시장( $USD 649.07K ).

보상과 수익: 회사가 수익성이 없는 동안 Chandler 의 보상이 증가했습니다.

CEO

Chandler Robinson (40 yo)

9.9yrs

테뉴어

US$1,778,655

보상

Dr. Chandler D. Robinson, M.D., MBA, MSc, Co-Founded Monopar Therapeutics Inc. in 2010 and has been Chief Executive Officer and Director since December 2014 and serves as President. Among his previous expe...

리더십 팀

이름	위치	테뉴어	보상	소유권
Christopher Starr	Co-Founder & Independent Executive Chairman of the Board	9.9yrs	US$264.04k	0.29% $ 302.6k
Chandler Robinson	Co-Founder	9.9yrs	US$1.78m	1.06% $ 1.1m
Andrew Cittadine	Chief Operating Officer	3.4yrs	US$911.14k	0.76% $ 801.4k
Karthik Radhakrishnan	CFO, Principal Accounting Officer & Principal Financial Officer	less than a year	데이터 없음	0.029% $ 31.2k
Patrice Rioux	Acting Chief Medical Officer	7.9yrs	데이터 없음	데이터 없음

5.7yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: MNPR 의 관리팀은 노련하고 경험 (평균 재직 기간 5.7 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Christopher Starr	Co-Founder & Independent Executive Chairman of the Board	9.9yrs	US$264.04k	0.29% $ 302.6k
Chandler Robinson	Co-Founder	9.9yrs	US$1.78m	1.06% $ 1.1m
Michael Brown	Independent Director	9.9yrs	US$126.04k	0.89% $ 948.2k
Raymond Anderson	Independent Director	7.6yrs	US$136.54k	0.10% $ 108.0k
Arthur Klausner	Independent Director	7.3yrs	US$128.54k	0.12% $ 124.1k
Kim Tsuchimoto	Director	1.7yrs	US$848.44k	0.22% $ 230.9k

8.8yrs

평균 재임 기간

65.5yo

평균 연령

경험이 풍부한 이사회: MNPR 의 이사회는 경험(평균 재직 기간 8.8 년)으로 간주됩니다.

Monopar Therapeutics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Monopar Therapeutics Inc., Annual General Meeting, Aug 05, 2024

Monopar Therapeutics Inc. Announces CFO Changes

Monopar Therapeutics Inc. Announces CFO Changes

Insufficient new directors

Monopar Therapeutics Inc., Annual General Meeting, Jun 28, 2022

Insufficient new directors

Recent updates

Price target increased by 51% to US$27.33

Monopar Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $19.200025 million.

New major risk - Shareholder dilution

Monopar Therapeutics Inc. has filed a Follow-on Equity Offering.

Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

Monopar Therapeutics Inc. Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

Monopar Therapeutics Inc. Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

New major risk - Market cap size

New major risk - Financial position

New major risk - Revenue and earnings growth

Monopar Therapeutics Inc., Annual General Meeting, Aug 05, 2024

Monopar Therapeutics Inc. Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr

Monopar Therapeutics Inc. Announces CFO Changes

Monopar Therapeutics Inc. Announces CFO Changes

Price target decreased by 38% to US$2.08

Monopar Therapeutics Inc. Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings

Monopar Therapeutics Inc Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

Price target decreased by 52% to US$4.05

Monopar Therapeutics Inc. Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

Nasdaq Grants Extension to Monopar Therapeutics to Regain Compliance with the Minimum Bid Price Requirement

Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Monopar Therapeutics Inc. Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers

Monopar Receives Clearance to Proceed with First-In-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

New major risk - Share price stability

New major risk - Share price stability

Monopar Therapeutics Inc. Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Monopar Therapeutics Receives Letter from Nasdaq Regarding Bid Price Requirement

Monopar Therapeutics Receives Letter from Nasdaq Regarding Bid Price Requirement

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Monopar Therapeutics Inc. Provides Update on Camsirubicin Clinical Trial

New major risk - Market cap size

Monopar Therapeutics Inc. Announces Encouraging Camsirubicin Phase 1b Trial Update

Price target decreased by 49% to US$9.80

Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?

Monopar Therapeutics Inc. Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin

Monopar Therapeutics Inc. Announces Projected Timeline of Upcoming Quarter 1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT

Price target increased by 12% to US$19.29

Monopar Therapeutics Inc. Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2

Monopar Therapeutics Inc. Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration

Monopar Therapeutics Inc. Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1B Trial

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Insufficient new directors

Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in Its Voice Trial for Severe Oral Mucositis

Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of Validive

Price target increased to US$32.67

We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate

Monopar Therapeutics Inc., Annual General Meeting, Jun 28, 2022

Insufficient new directors

Monopar Therapeutics Announces Resignation of Andrew P. Mazar as Member of the Board of Directors, Effective April 8, 2022

Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

Monopar Announces Clinical and Preclinical Program Updates

Price target increased to US$32.67

Monopar Therapeutics Inc. Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial

Price target increased to US$33.33

Monopar Therapeutics Inc. Expands Phase 2b/3 VOICE Clinical Trial to Europe

Monopar Therapeutics Inc. Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma

We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely

Monopar Therapeutics Inc. to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial At MASCC/ISOO

Monopar Therapeutics Inc. and Northstar Medical Radioisotopes Announce Patent Filing on Promising Radiopharmaceutical Discovery

Forecast to breakeven in 2025

Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Monopar Therapeutics Inc. Appoints Laura Kelly as Director of Clinical Operations

Monopar Announces First Patient Dosed in Its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)

Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer